Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Generic Musculoskeletal Disorders Drugs Market From 2025 to 2029?
In recent times, there has been a steady surge in the size of the generic musculoskeletal disorders drugs market. The growth is projected to increase from $0.06 billion in 2024 to $0.06 billion in 2025, maintaining a compound annual growth rate (CAGR) of 5.7%. Various factors have contributed to this growth in the historic period including the prevalence of musculoskeletal disorders, regulatory policies, development of healthcare infrastructure, patient awareness and education, as well as economic influences.
In the coming years, robust expansion is anticipated in the generic musculoskeletal disorders drugs market, reaching “$0.08 billion in 2029 with a compound annual growth rate (CAGR) of 6.9%. Factors such as a growing and aging population, rising markets, precision and personalized treatment innovations, healthcare reformations, and worldwide health developments are key to this projected growth. The forecast period will also likely spotlight trends that include the incorporation of technology in treatment modalities, government-led initiatives and healthcare guidelines, a focus shift towards alternative pain management solutions, wider acceptance of biosimilars, and breakthroughs in the development of generic drugs.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9433&type=smp
What Elements Are Contributing To Growth In The Generic Musculoskeletal Disorders Drugs Market?
The growth of the generic musculoskeletal disorders drugs market is expected to be driven by the widespread occurrence of arthritis. Arthritis is characterized by joint inflammation, including symptoms like joint pain and stiffness. Generic drugs for musculoskeletal disorders work to alleviate these symptoms and can also help treat muscle spasms related to this condition. As reported by the UK-based charity, Versus Arthritis, in March 2022, around 10 million individuals in the UK are suffering from osteoarthritis, of which 5.4 million have knee OA and 3.2 million have hip OA. Additionally, nearly 450,000 people have rheumatoid arthritis, and 190,000 have psoriatic arthritis. Consequently, these statistics indicate that over 20 million people grapple with musculoskeletal conditions, resulting in more than 30 million prescriptions for these problems at a cost of approximately £139 million in 2022-2023. Thus, the widespread prevalence of arthritis significantly contributes to the expansion of the generic musculoskeletal disorders drugs market.
Which Segments Are Detailed In The Global Generic Musculoskeletal Disorders Drugs Market Report?
The generic musculoskeletal disorders drugs market covered in this report is segmented –
1) By Treatment Type: Medication, Therapy, Surgery, Other Treatment Types
2) By Disorder Type: Osteoarthritis, Rheumatoid Arthritis, Spondylarthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Fibromyalgia, Other Disorder Types
3) By Route Of Administration: Oral, Parenteral, Other Routes
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy
Subsegments:
1) By Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics, Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologics
2) By Therapy: Physical Therapy, Occupational Therapy, Chiropractic Treatment, Massage Therapy
3) By Surgery: Joint Replacement Surgery, Arthroscopy, Spinal Surgery, Fusion Surgery
4) By Other Treatment Types: Lifestyle Modifications, Alternative Therapies, Assistive Devices
What Long-Term Trends Are Likely To Affect The Generic Musculoskeletal Disorders Drugs Market?
The global trend of strategic partnerships is becoming increasingly prevalent in the generic musculoskeletal disorders drugs market. Many market players are forming alliances to fortify their market position. An exemplification of this is the partnership between Mitsubishi Tanabe Pharma Corporation, based in Japan, and Eli Lilly and Company, a US-based pharmaceutical firm, in July 2022. This collaboration opens up opportunities for both companies to expand their product offerings and provide efficacious treatments for afflictions like diabetes and other diseases. Similarly, in February 2022, Pfizer Inc., a pharmaceutical and biotechnology entity from the US, entered into a partnership with the Sweden-based digital therapeutics company, Alex Therapeutics. This strategic alliance proffers patients with reliable, clinically approved, and personalized digital therapeutics.
Who Are The Key Contributors To Growth In The Generic Musculoskeletal Disorders Drugs Market?
Major companies operating in the generic musculoskeletal disorders drugs market include Pfizer Inc., Sanofi S.A., Eli Lilly and Company, Ampio Pharmaceuticals Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca plc, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Eisai Co. Ltd., Biogen Inc., Sino Biopharmaceutical Limited, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Mylan Pharmaceuticals Inc., Taisho Pharmaceutical Holdings Co. Ltd., Flexion Therapeutics Inc.
Get The Full Report Here:
Which Region Is Projected To Lead The Generic Musculoskeletal Disorders Drugs Market By 2025?
Asia-Pacific was the largest region in the generic musculoskeletal disorders drugs market in 2024. The regions covered in the generic musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9433&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model